Geert-Jan Mulder

Geert-Jan Mulder MD, co-founding partner of Forbion, is an experienced life sciences investor who led multiple deals in both Europe and the US.

Geert-Jan, Managing Partner, has a leading role in the Investment Team and the Portfolio as an experienced life sciences investor who led the firm’s successful investments and served on the boards (sometimes also in an executive capacity) of portfolio companies bluebird bio, (IPO on Nasdaq 2013), Acorda (IPO on Nasdaq 2006), PanGenetics (sold to Abbott in 2009), Transave (reverse-merger into Insmed in 2010), Exosome Diagnostics (sold to Bio-Techne), Promedior (sold to Roche in 2020) and KaNDy Therapeutics (sold to Bayer in 2020). Geert-Jan serves on the Board of several Forbion portfolio companies and in addition to his portfolio management activities, Geert-Jan closely works with management teams of various Forbion portfolio companies on clinical development strategies and regulatory matters, such as IND/ NDA filings, Special Protocol Approval (SPA), and US / EU Orphan designations for several products reflected by being a co-author of several Forbion and Forbion portfolio related scientific publications.

Before co-founding Forbion, Geert-Jan was an Investment Director at ABN AMRO Capital Life Sciences since 2001. Before that, at Byk Gulden (now Takeda) he served as a Clinical Research Manager, where his group was responsible for design and execution of early and late stage clinical trials forming the basis for two global product registrations: Daxas® and Alvesco® in fields of COPD and asthma. For both products he was a member of the Global Medical Marketing group. Before Byk, Geert-Jan was Medical Adviser at Searle (now Pfizer) in the field of Arthritis & Pain, being involved in the clinical development of Celebrex® and its European Advocate Development.

Geert-Jan received his Medical Degree from the University of Utrecht (NL), spent two years of residency in Obstetrics and Gynaecology at the University Medical Centre of Utrecht.